Mallinckrodt Receives Patent from US Patent and Trademark Office

Mallinckrodt has been granted a patent from the United States Patent and Trademark Office which contains composition claims directed to unique design, formulation, pharmacokinetic, and release characteristics of XARTEMIS XR. XARTEMIS XR (formerly known as MNK-795) is an investigational extended-release oral formulation of oxycodone and acetaminophen that has been studied with twice daily dosing for the management of acute pain in a post-surgical model. If approved, XARTEMIS XR will be the first oxycodone and acetaminophen combination medication specifically designed with immediate- and extended-release components. The patent, US Patent Number 8,658,631, was issued on 25 February 2014.

The release profile of XARTEMIS XR combines Mallinckrodt-proprietary technology and Depomed’s advanced Acuform drug delivery technology. Between the Mallinckrodt and Depomed patent families, Mallinckrodt believes XARTEMIS XR will have strong patent protection for its novel features.

“XARTEMIS XR, a key driver in our near-term pipeline, represents an important component of our strategy to unlock continued potential and grow our branded specialty pharmaceutical portfolio,” said Mark Trudeau, President and Chief Executive Officer, Mallinckrodt. “Mallinckrodt’s patent, which includes the product’s release profile, underscores our ability to effectively leverage our core formulation capabilities and partnerships.”

Acuform is a registered trademark of Depomed.